The first batch of Sputnik V, Russia’s Covid-19 vaccine, is likely to reach next week Kanpur's Ganesh Shankar Vidyarthi Medical College after which, the second and third phase of human clinical trials will be conducted.

According to an official, the Drugs Controller General of India (DCGI) had approved of this, following which, Dr. Reddy's Laboratories took the decision to conduct the trials.

"As many as 180 volunteers have registered for the trials. Head of the research Saurabh Agarwal will determine the dosage of the vaccine to be administered. One dose will be administered and the condition of volunteers will be monitored to determine whether they need further doses or not," the college principal R.B. Kamal said.

The condition of the volunteers will be checked from time to time and the data will be then analysed to determine the ability of the vaccine, he added.

The effect of the vaccine will be studied periodically for seven months after it is administered on the volunteers once, twice and thrice over 21 days.

The effects will be monitored and the results will be reported to the authorities after which a decision will be made.

“The Ethics Committee of the college has also given permission for the trails:, he said.

The vaccine has to be kept at cold temperatures ranging between -20 degrees to -70 degrees Celsius.

The lab entered into a partnership for the conduction of clinical trials and the Indian distribution of 100 million doses of Sputnik V with the Russian Direct Investment Fund (RDIF) in September.